RESULTS FROM WORK TO DEVELOP A PARSORTIX-BASED Her2 assay KIT SHOWCASED AT INTERNATIONAL LIQUID BIOPSY CONFERENCE ...

Mabel Mardones, MD, Rocky Mountain Cancer Centers, discusses the future of HR+/HER2– breast cancer treatment, focusing on the importance of biomarkers and the potential of SIRDs to improve patient ...

Medicaid expansion was associated with a slower decrease in receipt of guideline-concordant treatment, reduced delays in treatment initiation, and improved 2-year survival, according to researchers.

Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...

The PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial is 100% enrolled; expect to report topline data for this cohort in late Q1 2025 or Q2 2025Approximately $264 million in cash, cash equivalen ...

Cite this: The Role of Hormonal Therapy in the Management of Hormonal-Receptor-Positive Breast Cancer With Co-Expression of HER2 - Medscape - Sep 01, 2008. The article is based primarily on a ...

October 2024, saw significant FDA actions and clinical trial updates that shaped cancer treatment progress. Highlights include acalabrutinib’s approval for mantle cell lymphoma, T-DXd’s priority ...

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Friday.

A woman whose cancer has spread to her bones, back, pelvis and neck but has been denied a life-extending drug because she ...

A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...